Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma.
about
Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemiaThe combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphomaBendamustine: safety and efficacy in the management of indolent non-hodgkins lymphomaBendamustine: new perspective for an old drug in lymphoproliferative disorders.Randomized phase II study of a bendamustine monotherapy schedule for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma or mantle cell lymphoma (RABBIT-14).
P2860
Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Weekly treatment with a combin ...... indolent non-Hodgkin lymphoma.
@en
Weekly treatment with a combin ...... indolent non-Hodgkin lymphoma.
@nl
type
label
Weekly treatment with a combin ...... indolent non-Hodgkin lymphoma.
@en
Weekly treatment with a combin ...... indolent non-Hodgkin lymphoma.
@nl
prefLabel
Weekly treatment with a combin ...... indolent non-Hodgkin lymphoma.
@en
Weekly treatment with a combin ...... indolent non-Hodgkin lymphoma.
@nl
P2093
P2860
P1433
P1476
Weekly treatment with a combin ...... indolent non-Hodgkin lymphoma.
@en
P2093
Marc Heizmann
Mario Bargetzi
Martin Wernli
Nina Kotrubczik
Peter Moosmann
P2860
P304
P356
10.3109/10428190903275602
P577
2010-01-01T00:00:00Z